| Literature DB >> 34979602 |
Jae-Phil Choi1, Bo Kyeong Seo2.
Abstract
Since the introduction of effective antiretroviral therapy (ART) in the late 1990s, the prognosis for people living with human immunodeficiency virus (HIV) (PLWH) has dramatically improved. High-income countries like South Korea have had rapid declines in HIV-related deaths. Scientific advancements including pre-exposure prophylaxis (PrEP) and "undetectable equals untransmittable (U = U)" knowledge have contributed progress towards the goal of ending the acquired immune deficiency syndrome epidemic by 2030. However, the application of these advancements has been limited in South Korea. Evidence shows that HIV-related stigma and discrimination in healthcare settings remain strong in this region. We review key principles for stigma reduction and people-centered approaches in the era of U = U and identify three priorities: 1) immediate intervention in HIV stigma drivers in healthcare settings; 2) social stigma reduction on multiple levels; and 3) collaboration with key populations.Entities:
Keywords: Acquired Immunodeficiency Syndrome; Delivery of health care; Pre-exposure prophylaxis; Republic of Korea; Social stigma
Year: 2021 PMID: 34979602 PMCID: PMC8731251 DOI: 10.3947/ic.2021.0127
Source DB: PubMed Journal: Infect Chemother ISSN: 1598-8112
Contents of the guidance for healthcare facilities caring for people living with HIV
| All patients have the right to not be discriminated against in healthcare facilities and to receive the best equitable treatment regardless of gender, age, places of origin, ethnicity, sexual orientation, religion, language, socioeconomic status, disability, HIV status or other health conditions, drug use, or state of imprisonment or detention. |
| Healthcare providers should not refuse to treat HIV-positive patients (hospitalization or operation). HIV-positive patients should not be segregated at a specially designated facility, and their treatment should not be postponed without specific medical reasons ( |
| Healthcare providers should discuss with patients and obtain their informed consent before HIV testing. Healthcare providers should explain the possibility of false-positive results on the screening test and provide a follow-up evaluation plan. |
| Healthcare providers should keep patients' HIV status confidential during the course of care and not reveal any patient's HIV status to third parties without consent. Special markings on a patients' bed or chart should not be placed in a noticeable manner. If a marking is necessary for infection control purposes, it should be detectable to only healthcare providers. |
| During counselling, healthcare providers must not use verbal or nonverbal expressions communicating disgust or contempt regarding HIV status or sexual orientation. Medical staff must respect patient dignity and self-determination. |
| Healthcare providers should comply with the standard precaution principles in all clinical circumstances for all patients. In treating HIV-positive patients, healthcare providers do not have to wear unnecessary protective gear in clinical situations other than invasive procedures or when dealing with blood. Medical staff should follow common blood-borne pathogen precautions during surgery for the safety of patients and medical staff. |
| Medical societies should acknowledge the negative influence of discrimination on the health of PLWH and promote healthcare providers' understanding of patient rights. It is also medical societies' responsibility to deliver education to healthcare providers that helps them to understand PLWH and reduces social stigma and discrimination. |
| Public health authorities (state or local governments) should prevent discrimination against PLWH and provide proper resources for infection control in healthcare facilities. They also have to implement auditing measures to monitor the protection of patient rights and proper infection control. |
HIV, Human immunodeficiency virus; PLWH, people living with HIV.
Scientific evidences for the U = U campaign.
| Study | HPTN052 [ | PARTNER1 [ | OPPOSITE ATTRACT STUDY [ | PARTNER2 [ |
|---|---|---|---|---|
| Design | Randomized Controlled Trial | Prospective observational study | Prospective observational study | Prospective observational study |
| Participant enrollment | Africa, Southeast Asia and America | 14 European countries | Australia, Brazil, Thailand | 14 European countries |
| 1,763 serodiscordant couples (98% heterosexual) | 548 couples | 343 serodiscordant couples | 782 serodiscordant Gay couples | |
| Heterosexual (HIV + men n = 269, HIV + women n = 279) | ||||
| 340 MSM | ||||
| Condition of HIV positive partner | 32 missing | Viral load <200 copies/mL = 267 (78%) | Viral load <200 copies/mL = 774/781 (99%) | |
| 760 (85.5%) | ||||
| Undetectable HIV viral load | Mean CD4 = 628.8/mm3 (n = 292.8) | CD4 >350/mm3 = 730/781 (93%) | ||
| Eligible couple year (Median follow up duration, years) | (5.5) | 1,138 (1.3) | 588.4 (1.7) | 1,593 (2.0) |
| Condomless sexual relationship | Heterosexual: | 16,800 times | 76,088 times | |
| 36,000 times | ||||
| MSM: 22,000 times | ||||
| Newly developed HIV infection (cases) | Early treatment group: 19 | 10 MSM, 1 heterosexual | 3 new HIV infections | 15 new HIV infections |
| Phylogenetically linked transmission | 0a | 0 | 0 | 0 |
| Other Sexually transmitted infections | Not checked | 89/888 (10%) | 46/343 (13%) | 185/779 (24%) |
aIn HTN052 study, phylogenetically linked infections after treatment were occurred in 3 patients from early treatment group and 5 from delayed groups.
U = U, Undetectable = Untransmittable; HIV, human immunodeficiency virus; MSM, men who have sex with men.